China Warns of Countermeasures After US Bans Imports from Three Chinese Biotech Firms

The dispute extends beyond trade into reputational risk: a forced-labor designation can affect a company's access to Western supply chains and financing regardless of the underlying facts, and Beijing's vow of countermeasures signals the issue is now a bilateral bargaining chip. For biotech and broader RWA-adjacent supply chains, the open question is whether such import bans become a template applied to other sectors, and how Chinese retaliation targets US firms in response.